- Home
- ZENA vs LPTX Comparison
ZENA vs LPTX Comparison
Compare ZENA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- LPTX
- Stock Information
- Founded
- ZENA 2017
- LPTX 2011
- Country
- ZENA Canada
- LPTX United States
- Employees
- ZENA N/A
- LPTX N/A
- Industry
- ZENA
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENA
- LPTX Health Care
- Exchange
- ZENA NYSE
- LPTX Nasdaq
- Market Cap
- ZENA 109.4M
- LPTX 119.6M
- IPO Year
- ZENA N/A
- LPTX N/A
- Fundamental
- Price
- ZENA $3.59
- LPTX $0.30
- Analyst Decision
- ZENA Strong Buy
- LPTX Buy
- Analyst Count
- ZENA 1
- LPTX 2
- Target Price
- ZENA $9.00
- LPTX $8.00
- AVG Volume (30 Days)
- ZENA 10.0M
- LPTX 3.3M
- Earning Date
- ZENA 01-01-0001
- LPTX 08-11-2025
- Dividend Yield
- ZENA N/A
- LPTX N/A
- EPS Growth
- ZENA N/A
- LPTX N/A
- EPS
- ZENA N/A
- LPTX N/A
- Revenue
- ZENA $1,744,794.00
- LPTX N/A
- Revenue This Year
- ZENA N/A
- LPTX N/A
- Revenue Next Year
- ZENA N/A
- LPTX N/A
- P/E Ratio
- ZENA N/A
- LPTX N/A
- Revenue Growth
- ZENA 24.50
- LPTX N/A
- 52 Week Low
- ZENA $1.41
- LPTX $0.22
- 52 Week High
- ZENA $12.43
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- LPTX 30.76
- Support Level
- ZENA N/A
- LPTX $0.27
- Resistance Level
- ZENA N/A
- LPTX $0.30
- Average True Range (ATR)
- ZENA 0.00
- LPTX 0.04
- MACD
- ZENA 0.00
- LPTX -0.01
- Stochastic Oscillator
- ZENA 0.00
- LPTX 7.11
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The company operates in software development technology, sales, and distribution. The company is also developing a drone manufacturing, sales, and distribution business. It generates revenue from software licensing and subscription agreements, software support and maintenance, and technology consulting services.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .